New Oral Anticoagulants and Their Reversal Agents.

about

Noncontrast Computed Tomography Markers of Intracerebral Hemorrhage Expansion.Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal.Reversal Strategies for Intracranial Hemorrhage Related to Direct Oral Anticoagulant Medications

P2860

Q39176601-922EB96E-5C19-41CF-974C-4D957F9BFB23 Q39452481-032CF66A-42D3-4C30-AC8D-896CE638CF4C Q57177164-A8849553-7DF7-45E8-8278-31FA018542E0

P2860

New Oral Anticoagulants and Their Reversal Agents.

Item

http://www.wikidata.org/entity/Q38970532

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

New Oral Anticoagulants and Their Reversal Agents.

@en

type

Item

label

New Oral Anticoagulants and Their Reversal Agents.

@en

prefLabel

New Oral Anticoagulants and Their Reversal Agents.

@en

P1476

New Oral Anticoagulants and Their Reversal Agents.

@en

P2093

Andrea Morotti

http://www.w3.org/2001/XMLSchema#string

Joshua N Goldstein

http://www.w3.org/2001/XMLSchema#string

P2860

Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians

How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation

Absolute and Relative Contraindications to IV rt-PA for Acute Ischemic Stroke.

The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis

A specific antidote for dabigatran: functional and structural characterization

Dabigatran: how the drug company withheld important analyses

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

Dabigatran versus warfarin in patients with atrial fibrillation

Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

Idarucizumab for Dabigatran Reversal

P2888

s11940-016-0430-5

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11940-016-0430-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27696178

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation

New Oral Anticoagulants and Their Reversal Agents.

about

P2860

P2860

New Oral Anticoagulants and Their Reversal Agents.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921